Search results
Results from the WOW.Com Content Network
It is manufactured and sold in the United States by Celgene under the trade name Abraxane where it is designated as an orphan drug as first-line treatment, in combination with gemcitabine, for the orphan disease "metastatic adenocarcinoma of the pancreas".
The most common grade 3 or 4 adverse events in MPACT for ABRAXANE plus gemcitabine versus gemcitabine alone were neutropenia (38% vs. 27%, respectively), fatigue (17% vs. 7%) and peripheral ...
Gemcitabine, sold under the brand name Gemzar, among others, [1] is a chemotherapy medication used to treat cancers. [2] It is used to treat testicular cancer , [ 3 ] breast cancer , ovarian cancer , non-small cell lung cancer , pancreatic cancer , and bladder cancer .
Ho-hum for AbraxaneFindings from a phase 3 study of Abraxane. Celgene was one of several companies presenting at the American Society of Clinical Oncology, or ASCO, annual meeting in Chicago this ...
In the MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study, ABRAXANE plus gemcitabine demonstrated a 59% increase in one-year survival (35% vs. 22%, p=0.0002) and demonstrated double ...
He is the inventor of the drug Abraxane, which is used for lung, breast, and pancreatic cancer. Soon-Shiong is the founder of NantWorks, a network of healthcare, biotech, and artificial intelligence startups; [ 2 ] an adjunct professor of surgery and executive director of the Wireless Health Institute at the University of California, Los ...
For premium support please call: 800-290-4726 more ways to reach us
In the United Kingdom, the National Institute for Health and Care Excellence (NICE), in a draft guidance issued in 2014, rejected the use of Abraxane in treatment due to concerns of side effects, efficacy, and cost relative to Gemzar (gemcitabine). [10] However, on 18 May 2017 NICE issued a reappraisal for the use of Abraxane in the UK.